BriaCell Therapeutics (TSE:BCT) Shares Down 55.7% – Should You Sell?

BriaCell Therapeutics Corp. (TSE:BCT)’s share price traded down 55.7% during trading on Thursday . The stock traded as low as C$6.66 and last traded at C$6.74. 235,492 shares traded hands during trading, an increase of 450% from the average session volume of 42,809 shares. The stock had previously closed at C$15.22.

BriaCell Therapeutics Stock Down 55.7%

The company has a market cap of C$12.70 million, a price-to-earnings ratio of -0.20 and a beta of 3.42. The business has a 50-day simple moving average of C$12.63 and a two-hundred day simple moving average of C$14.62.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.